Analyst Upgrades

• Raymond James upgraded Research in Motion (RIMM) to outperform from market perform based on valuation. The firm has a $70 price target on the stock.
• Macquarie upgraded Halliburton (HAL) to outperform from neutral and has a $40 price target on the stock. The firm said recent pressure pumping activity is above their expectations and pricing has firmed.
• Canaccord upgraded Baldor Electric (BEZ) to buy from speculative buy, citing improving business trends and the upcoming mandatory transition to premium efficiency motors. The firm has a $47 price target on the stock.
• Wells Fargo upgraded Williams-Sonoma (WSM) to outperform from market perform.
• Medco Health (MHS) was upgraded to conviction buy from buy at Goldman.
• Repsol (REP) was upgraded to buy from neutral at BofA/Merrill.

Continue reading Analyst Calls: AMZN, BCS, BEZ, DOW, FSLR, HAL, HBI, PFE, RIMM, WSM ...

Analyst Calls: AMZN, BCS, BEZ, DOW, FSLR, HAL, HBI, PFE, RIMM, WSM ... originally appeared on BloggingStocks on Mon, 28 Jun 2010 11:40:00 EST. Please see our terms for use of feeds.

"Cellcom Israel (CEL), Israel's leading mobile-phone company, delivered decent fourth-quarter results, highlighted by modest +4% top-line growth but more robust +11% net income growth," says Amy Calistri.

The editor of The Daily Paycheck explains, "That caps off a fiscal year that saw impressive expense control, and a shift to higher-margin offerings. So the full-year results were even more dramatic than the quarterly trend, with net income soaring almost +20%."

Continue reading Cellcom Israel (CEL): Dividends and Shekels

Cellcom Israel (CEL): Dividends and Shekels originally appeared on BloggingStocks on Fri, 02 Apr 2010 10:40:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Citigroup initiated Wyeth (NYSE: WYE) with a Hold rating and $49 target. The firm believes the upside potential from bapineuzumab is masking the company's unfavorable average EPS and revenue growth forecast versus the industry.
  
• Piper believes 3SBio Inc (NASDAQ: SSRX) is the market leader in a largely underpenetrated EPO market in China and sees limited downside risk. Shares were assumed with a Buy rating and $12 target.
  
• RBC Capital initiated Cellcom Israel (NYSE: CEL) and Partner Communications (NASDAQ: PTNR) with Outperform ratings and targets of $40 and $30, respectively. RBC said they have defensive appeal given their predictable earnings stream.

• HCP (NYSE: HCP), Nationwide Health Properties (NYSE: NHP) and Medical Properties Trust (NYSE: MPW) were initiated with Market Perform ratings at Wachovia.
  
• SanDisk (NASDAQ: SNDK) was assumed with an Above Average rating and $20.50 target at Caris.

Analyst initiations: WYE, SSRX, CEL and PTNR originally appeared on BloggingStocks on Fri, 18 Jul 2008 11:40:00 EST. Please see our terms for use of feeds.

"As is the case with most countries in the Middle East, Israel rarely comes up in discussions of global 'safe havens', notes John Christy.

The editor of The Forbes International Investment Report explains, "But so far this year, Israel has been a pretty good place to hide from Wall Street's woes." Here he looks at one Israeli favorite, Cellcom Israel (NYSE: CEL).

"Putting stereotypes about risk aside, Israel offers a lot of interesting opportunities, even for fairly conservative investors. Cellcom Israel is a prime example. The company is Israel's largest mobile phone service provider, with sales of $1.6 billion in 2007.

"Since February 2007, the company has had a dual listing on both the New York and Tel Aviv stock exchanges. Discount Investment Corp. Ltd., one of Israel's largest business groups, owns just over 50% of the company.

"With 3.1 million subscribers, Cellcom has a 34% share of Israel's mobile telecom services market. Roughly three-quarters of Cellcom's subscribers are individuals, and the remaining 25% are corporate customers.

Continue reading Shalom: Forbes expert calls on Cellcom Israel (CEL)

Shalom: Forbes expert calls on Cellcom Israel (CEL) originally appeared on BloggingStocks on Thu, 19 Jun 2008 10:39:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Merriman upgraded shares of Syneron Medical (NASDAQ:ELOS) to Buy from Neutral following the Q1 results to reflect the introduction of LipoLite and the company's global distribution channel. They believe shares can trade towards the $22-$26 level.
  
• Jefferies upgraded Cellcom Israel (NYSE:CEL) to Buy from Hold following the company's Q1 results to reflect its improved EBITDA outlook.
  
• Morgan Keegan upgraded GATX (NYSE:GMT) to Outperform from Market Perform as they believe the company has increased opportunities to deploy capital given the current state of the market for railcars, which should result in share outperformance.
  
• Suntrust raised TNS, Inc (NYSE:TNS) to Buy from Neutral citing improved execution and the global shift towards electronic transactions.

• Chevron (NYSE:CVX) was raised at UBS to Buy from Neutral.
  
• RBC Capital upgraded TeleTech Holdings (NASDAQ:TTEC) to Sector Perform from Underperform.
  
• Citigroup upgraded SINA Corp (NASDAQ:SINA) to Buy from Hold.

Analyst upgrades: ELOS, CEL, GMT and TNS originally appeared on BloggingStocks on Thu, 15 May 2008 10:54:00 EST. Please see our terms for use of feeds.

Israeli cell phone carrier Cellcom Israel Ltd. (NYSE: CEL) is trading higher on almost 4 times average daily volume. While no reason has been given for the surge in volume, this weekend is extremely important for the Israel cell phone industry. Starting in December, number portability takes effect; meaning that customers will be free to take their phone numbers with them to any carrier they choose. No one is quite sure what will happen, but the anticipated marketing onslaught to persuade consumers to switch carriers, hasn't really materialized.

Three weeks ago the company reported a rise in the number of subscribers and a 47 percent jump in income from data and content and that revenue rose 7.2 percent to $392 million. Net profit rose more than expected in the third quarter, boosted by cost cuts and sharply higher revenue from data and content services. Israel's largest mobile phone operator posted net profit of $67 million, or 68 cents per diluted share, compared with $33 million or 34 cents a share a year earlier.

With a PE of 15.50 and a dividend yield of 8.5%, the stock is an attractive play for investors who want some exposure to the Israeli domestic economy.

But it's important to keep in mind that with cellular penetration of 120% and potential surging marketing costs just to keep existing customers, let alone trying to get new ones, Cellcom may be in for some volatility.

Aaron Katsman is the lead Portfolio Manager and Managing Director of America Israel Investment Associates, LLC. and Senior Editor of IsraelNewsletter.com. Disclosure: Writer has no position in any stock mentioned as of 11/29/07.

Israeli Cellcom advances on high volume originally appeared on BloggingStocks on Sat, 01 Dec 2007 13:10:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Benchmark started Oracle Corp (NASDAQ: ORCL) with a Hold rating.

• JP Morgan initiated Helicos BioSciences (NASDAQ: HLCS) with a Neutral rating based on the potential of its single-molecule genetic sequencing platform but noted that commercialization carries near-term risk.

• Hambrecht believes Clean Energy Fuels' (NASDAQ: CLNE) total addressable market is over $20B given the company's focus on natural gas vehicle fuel for return-to-base applications and started shares with a Buy rating.

• Jefferies wants to see China Sunergy (NASDAQ: CSUN) demonstrate that its silicon wafer suppliers can meet aggressive ramping plans before becoming more positive on the stock, starting shares off with a Hold rating...

• Lehman started Greenlight Capital Re (NASDAQ: GLRE) with an Equal Weight rating.

• Cellcom Israel (NYSE: CEL) and Partner Communications (NYSE: PTNR) were initiated with Buy ratings at Citigroup.

Analyst initiations 7-05-07: CSUN, HLCS and ORCL originally appeared on BloggingStocks on Thu, 05 Jul 2007 10:45:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• CVS Corp (NYSE: CVS) was reinstated at Credit Suisse with an Outperform and at JP Morgan with Neutral ratings.

• Express Scripts (NASDAQ: ESRX) was reinstated at Credit Suisse with an Outperform rating, up from its Neutral rating, and resumed at Bank of America with a Buy rating. JP Morgan reinstated Express Scripts share with an Overweight rating.

• Goodrich Petroleum (NYSE: GDP) was initiated with an Overweight rating at JP Morgan.

• Jefferies initiated Cellcom Israel Ltd (NYSE: CEL) with a Buy rating and $21 target.

• CIBC initiated 3SBio Inc (NASDAQ: SSRX) with a Sector Outperformer rating and $17 target; the firm said 3SBio Inc offers the broadest range of BioGenerics in the Chinese market and views the company as an execution story and country play.

• Cowen started G-III Apparel Group, Ltd (NASDAQ: GIII) with an Outperform rating based on expectations of market share growth to be driven by new brands and products.

• BMO Capital Markets expects Riverbed Technology, Inc (NASDAQ: RVBD) with a Market Perform rating.

• Lazard started Synta Pharmaceuticals Corp (NASDAQ: SNTA) with a Buy rating; Bear Stearns initiated shares of Synta with an Outperform rating.

Analyst initiations 3-19-07: CVS Corp reinstated at JP Morgan & Credit Suisse originally appeared on BloggingStocks on Mon, 19 Mar 2007 11:31:00 EST. Please see our terms for use of feeds.